Informazioni sul prodotto
- Imidazo[1,2-a]pyridinium, 3-(diphenylphosphinothioyl)-2-methyl-1-[(2E)-3-phenyl-2-propen-1-yl]-, bromide (1:1)
ML 154 is a new non-addictive, acetylcholine receptor agonist that has shown promise as an effective treatment for individuals with diabetes. It has been shown to have affinity constants of 3.1 nM and 2.8 nM for the mouse and rat muscle tissue respectively. ML 154 also penetrates the esophagus and can be detected in physiological levels in the blood stream following intraluminal administration in rats. This drug has been shown to increase locomotor activity in mice, which may be due to its ability to induce acetylcholine release from nicotinic receptors on skeletal muscle cells. ML 154 also stimulates protein synthesis, which may be due to its ability to bind to acetylcholine receptors on cardiac myocytes and stimulate these cells to contract.
